Triple-class virologic failure in HIV-infected patients undergoing antiretroviral therapy for up to 10 years
about
Added value of deep sequencing relative to population sequencing in heavily pre-treated HIV-1-infected subjectsDeterminants of access to experimental antiretroviral drugs in an Italian cohort of patients with HIV: a multilevel analysis.Second-line antiretroviral therapy in a workplace and community-based treatment programme in South Africa: determinants of virological outcomeHIV treatment as prevention: systematic comparison of mathematical models of the potential impact of antiretroviral therapy on HIV incidence in South AfricaLong-term virological outcome in children on antiretroviral therapy in the UK and Ireland.The successful application of a national peer advisory committee for physicians who provide salvage regimens to heavily antiretroviral-experienced patients in mexican human immunodeficiency virus clinicsRisk of triple-class virological failure in children with HIV: a retrospective cohort studyPredictors for the emergence of the 2 multi-nucleoside/nucleotide resistance mutations 69 insertion and Q151M and their impact on clinical outcome in the Swiss HIV cohort study.Neuropsychiatric complications of aging with HIV.CD4 cell count and the risk of AIDS or death in HIV-Infected adults on combination antiretroviral therapy with a suppressed viral load: a longitudinal cohort study from COHEREViral suppression following switch to second-line antiretroviral therapy: associations with nucleoside reverse transcriptase inhibitor resistance and subtherapeutic drug concentrations prior to switchHigher rates of triple-class virological failure in perinatally HIV-infected teenagers compared with heterosexually infected young adults in EuropeOptimizing antiretroviral therapy in adolescents with perinatally acquired HIV-1 infection.Predictors of CD4(+) T-cell counts of HIV type 1-infected persons after virologic failure of all 3 original antiretroviral drug classes.Cohort Profile: Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord.Efficacy, tolerability and risk factors for virological failure of darunavir-based therapy for treatment-experienced HIV-infected patients: the Swiss HIV Cohort Study.Long-term clinical, immunological and virological outcomes of patients on antiretroviral therapy in southern Myanmar.Combination antiretroviral therapy.Impact of etravirine on hospitalization rate between 2005 and 2011 among heavily treated HIV-1-infected individuals on failing regimens.
P2860
Q28478134-FF169470-06FD-4544-A5D2-3CBE0CE0C775Q34159738-07A7EA1C-6D00-488F-81C1-E81FA75685ABQ34292437-45F95EF0-5E7F-49B4-9CE7-BDE587EC2950Q34339465-42A11A4F-23B6-4449-9D14-36D51357C42FQ34410947-DE8AB38E-5A85-4317-9F63-5FFA1BDFC96EQ34802051-51A51C1D-CE13-4A8B-A7F2-5D18B1DDEAC2Q34997180-74082341-132E-49F4-AFCC-C9AEC36CCB0CQ35057734-36BD1268-8A81-4DF5-BFC3-06BDDD8FCD43Q35568407-4B46861B-9B1B-4BE9-99B9-2A518BE25ACDQ35842386-991384D3-4E7A-4717-9215-5D5904363C9FQ37582314-83CAA663-C3FF-4CC5-A826-2D7D1AA6268DQ37631931-DD67A948-76CF-4D9D-8104-E00C77EF3FF5Q37816391-134DA070-2FD7-4BD5-8352-3FF5B0879895Q38428663-693FBDA2-48E3-4378-8A3C-FE0631E7388FQ40444741-C1E13ABB-550B-4A2E-B8C7-16696748B60AQ44246520-E8010480-1455-4AE9-8164-7BBB980C20EFQ50053558-78122DD6-272D-4281-A836-1992B66514F9Q51720301-0E4C78A3-C5D7-4C65-92B7-90991D2D4CB8Q55650665-2F7CA837-EA1A-445B-8945-D89F1A2C4150
P2860
Triple-class virologic failure in HIV-infected patients undergoing antiretroviral therapy for up to 10 years
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Triple-class virologic failure ...... ral therapy for up to 10 years
@ast
Triple-class virologic failure ...... ral therapy for up to 10 years
@en
type
label
Triple-class virologic failure ...... ral therapy for up to 10 years
@ast
Triple-class virologic failure ...... ral therapy for up to 10 years
@en
prefLabel
Triple-class virologic failure ...... ral therapy for up to 10 years
@ast
Triple-class virologic failure ...... ral therapy for up to 10 years
@en
P2093
P2860
P50
P1476
Triple-class virologic failure ...... ral therapy for up to 10 years
@en
P2093
Andrew N Phillips
Bernard Masquelier
Bruno Ledergerber
Carlo Torti
Cristina Mussini
Céline Fabre-Colin
Daniel Podzamczer
Federico García
Genèvieve Chêne
Giota Touloumi
P2860
P304
P356
10.1001/ARCHINTERNMED.2009.472
P407
P50
P577
2010-03-01T00:00:00Z